As an SMN2 splicing modifier, special attention should be paid to hepatotoxicity, rash risk, and drug interactions when using Evrysdi tablets. The following will provide a detailed explanation of relevant precautions to help ensure safe medication.

1. Liver toxicity monitoring

Risperidone may cause liver dysfunction, manifested as elevated transaminase or bilirubin levels. Regular monitoring of liver function indicators is necessary during treatment, especially in the early stages of medication. If symptoms of liver damage such as jaundice and fatigue occur, immediate medical evaluation should be sought. Patients with liver dysfunction do not need to adjust the dosage, but monitoring frequency needs to be strengthened.

2 Skin rash management

Rash is a common adverse reaction, often manifested as mild erythema or itching. If a severe rash occurs (such as Stevens Johnson syndrome), the medication should be permanently discontinued. Mild rash can be treated symptomatically, while closely monitoring its progression. Avoid direct sunlight exposure during medication to reduce the risk of photosensitive rash.

3 drug interactions

(1) CYP3A4 impact

Strong CYP3A4 inhibitors (such as clarithromycin) may increase the blood concentration of risperidone and should be avoided in combination or adjusted in dosage. Strong CYP3A4 inducers (such as rifampicin) may reduce efficacy and should be used with caution.

(2) Specific drugs

Combined use with warfarin may increase the risk of bleeding, and INR values need to be monitored. The effectiveness of hormonal contraceptives may be weakened, and it is recommended to use non hormonal contraceptive measures. Proton pump inhibitors may affect absorption, it is recommended to take them every 2 hours.

(3) The impact of food

Grapefruit or grapefruit juice may inhibit CYP3A4 enzyme, increase drug exposure, and should be avoided during treatment. A high-fat diet may delay absorption, but it does not affect overall bioavailability.